DRUG · Unmapped registry intervention
PF-07220060 CDK4 inhibitor
Find medicine records ·
Find other trials using this name
Clinical trial
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Fulvestrant
Normalized identity: fulvestrantView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Everolimus
Normalized identity: everolimusView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Exemestane
Normalized identity: exemestaneView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Advanced or Metastatic Breast Cancerunresolved
Interventions
FulvestrantDRUG · verified · RxNorm: fulvestrant
EverolimusDRUG · verified · RxNorm: everolimus
ExemestaneDRUG · verified · RxNorm: exemestane
Sponsors & collaborators
Pfizerlead sponsor
Mapped research locations
Los AngelesCalifornia, United States3AnkaraTurkey (Türkiye)3IrvineCalifornia, United States2HoustonTexas, United States1LondonUnited Kingdom1Washington D.C.District of Columbia, United States1ShanghaiShanghai Municipality, China1Porto AlegreRio Grande do Sul, Brazil1ChangshaHunan, China1OsakaJapan1WuhanHubei, China1BillingsMontana, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06105632 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.